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a b s t r a c t
Frequency of additional chromosomal abnormalities in chronic myeloid leukemia (CML) is estimated to
be 7% in chronic phase and increases to 40–70% in advanced disease. Progression of CML from chronic
phase to accelerated phase or blast crisis is often associated with secondary chromosomal aberrations.
We report an exceptional case of CML as debut in lymphoblastic blast crisis and a subsequent progression
in myeloblastic blast crisis with rare cytogenetic abnormalities.
& 2013 The Authors. Published by Elsevier Ltd.
1. Introduction
Chronic myeloid leukemia (CML) is a clonal malignant disorder of a
pluripotent hematopoietic stem cell characterized by the presence of
the reciprocal translocation t(9;22)(q34;q11), which generates the
Philadelphia (Ph) chromosome. Frequency of additional chromosomal
abnormalities has an incidence of 7% in chronic phase and increases to
40–70% in advanced disease/blast crisis [1,2]. Progression from chronic
phase to accelerated phase or blast crisis is often associated with
secondary chromosomal aberrations such as trisomy 8, trisomy 19,
duplication of the Ph chromosome, isochromosome 17q (leading to
the loss of p53 gene on 17p), acquisition of t(1;21) or translocations
and inversions associated with AML/myelodysplasia [3], which trans-
lates a genomic instability of CML cells and the appearance of BCR-
ABL1 kinase mutations, both of which can confer resistance to tyrosine
kinase inhibitors (TKIs) [4,5].
Herein we report an exceptional case of CML diagnosed in
lymphoblastic blast crisis which subsequently suffered a progres-
sion to myeloblastic blast crisis with rare cytogenetic abnormalities.
2. Case report
A 65-year-old woman presented with profuse sweating and
weakness for 3 months and a leukocytosis of 20010e9/L with more
than 80% blasts in peripheral blood. A bone marrow aspirate was
performed showing 50% lymphoid blasts with aberrant myeloid
markers: CD34þ CD45þw DRþ CD38þ cTdTþ cCD79aþ CD19þ
CD10þ CD20 CD24þ cIgM sIg CD7þ CD13þ CD33þ/ .
Genetic testing for Philadelphia chromosome was done by
ﬂuorescence in situ hybridization (FISH) and conventional cytoge-
netic analysis (karyotyping). The BCR-ABL fusion gene was assessed
by RT-PCR. BCR-ABL rearrangement was detected by FISH in 96% of
the bone marrow cell population and monosomy 7 in 71% of them
(Fig. 1A and B). Cytogenetic features were as follows: 45,XX,-7,t(9;22)
(q34;q11.2)[20] (Fig. 2A). The number of BCR-ABL transcripts at
diagnosis was 70%.
The patient received chemotherapy based on anthracycline,
vincristine and steroids and imatinib at doses of 600 mg daily with
intrathecal chemotherapy, achieving complete remission of acute
leukemia and chronic phase regression. Immediately after treat-
ment, a new FISH assay in peripheral blood was performed and
showed BCR-ABL rearrangement in 92% of cells, while monosomy
7 was not detected (Fig. 1C and D). Karyotype at that time was 46,
XX,t(1;6),t(9;22)(q34;q11.2)[10]/46,XX[10].
Afterwards, the patient received consolidation therapy with
vincristine and daunomycin plus imatinib, which was tapered to
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400 mg daily due to dyspnea and marked palpebral and ankle
edema. Overall, she showed a good clinical outcome with 3.3%
bcr-abl transcripts three months after diagnosis.
Nevertheless, one week after this last determination, the
patient returned to consultation due to headache and B symptoms.
WBC showed leukocytosis of 258109/L with 87% blasts. A new
bone marrow had inﬁltration by 75% blasts of myeloid lineage
consistent with myeloid blast crisis of CML. Immunophenotype of
this blastic population was CD45þ CD34þd CD117þd DRþ
CD38þ CD13þ CD33þ CD11b CD64 CD56 CD7þ/ CD9þd
CD123þ showing the following karyotypic changes: 46,XX,t(1;6)
(q22;q21),del(4)(p14),t(9;22)(q34;q11.2),der(11)add(11)(p14)add(11)
(q23),add(17)(q1221)[20] (Fig. 2B). The patient also developed a
T315I bcr-abl mutation detected by DNA sequencing.
Fig. 1. (A) At diagnosis. Interphase FISH, Vysis dual-fusion probe set. Green: BCR; red: ABL; yellow: fused BCR and ABL signals corresponding to der(9) and der(22)
translocation products. (B) At diagnosis. Interfase FISH, Vysis dual color probe set. Green: chromosome 7 centromere; red: locus 7q31. Interphase cells showing one
centromere and one 7q31 signal indicating monosomy 7. (C) After treatment: rearrengement BCR/ABL (92%). (D) After treatment: monosomy 7¼0%. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. (A) Karyotype at diagnosis (lymphoblastic blast crisis): 45,XX,-7,t(9;22)(q34;q11.2)[20]. (B) Karyotype at relapse (myeloblastic blast crisis): 46,XX,t(1;6)(q22;q21),
del(4)(p14),t(9;22)(q34;q11.2),der(11)add(11)(p14)add(11)(q23),add(17)(q1221)[20].
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In spite of treatment with steroids, she suffered a seizure and a
parenchymal hematoma was observed in a cranial TC-scan, and
subsequently died.
3. Discussion
In the current study we report on a patient with CML diagnosed
with lymphoblastic blast crisis with monosomy 7 in 71% of bone
marrow cells; karyotype was 45,XX,-7,t(9;22)(q34;q11.2)[20] at
diagnosis. After treatment, monosomy 7 was not detected and a t
(1;6) was observed upon regression into chronic phase. After-
wards, a subsequent myeloid blast crisis was associated with the
following karyotype: 46,XX,t(1;6)(q22;q21),del(4)(p14),t(9;22)
(q34;q11.2),der(11)add(11)(p14)add(11)(q23),add(17)(q12–21)[20].
In addition, the T315I bcr-abl mutation was also detected.
These ﬁndings would suggest the presence of a leukemic stem
cell carrying the t(9;22) as the primary event in the onset of the
disease. A second hit would be the acquisition of a monosomy 7
in a cell committed to lymphoid lineage, which might confer a
proliferative advantage giving rise to the lymphoid blast crisis,
when diagnose was made. At this time point, it was also observed
the presence of a small fraction of leukemic cells, which would be
committed to myeloid lineage, carrying a t(1;6) in addition to the t
(9;22), which latter on gave rise to the myeloid blast crisis. At this
time, the emergence of several additional cytogenetic abnormal-
ities was observed and T315I mutation was found, as an indicative
fact of refractoriness to treatment.
Thus, treatment for acute lymphoblastic leukemia based on
chemotherapy and imatinib successfully erradicated the clone
involved in lymphoblastic blast crisis while allowing a clonal
selection and subsequent expansion of myeloid cells carrying the
t(1;6). Very few cases of lineage switch in CML have been reported
in the literature before [6–9] and during the imatinib era [10].
Furthermore, to our knowledge, this is the ﬁrst report describing
sequential lymphoid and myeloid blast crisis with differentiated
cytogenetic abnormalities.
In summary, this is an interesting case depicting the underlying
clonal heterogeneity of CML in evolution as well as the clonal
selection under combined treatment with chemotherapy plus TKIs.
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